Explanatory Note
This Amendment No. 1 (“Amendment No. 1”) to Schedule 13D supplements and amends the statement on Schedule 13D originally filed with the
Securities and Exchange Commission (the “SEC”) on April 19, 2024 (together, as so amended, the “Schedule 13D”) jointly by each of the following persons (collectively, the “Reporting Persons”): Nathan D. Hukill
(“Mr. Hukill”), a citizen of the United States, CR Group L.P., a Delaware limited partnership (“CR Group”), CRG Partners III – Parallel Fund “A” L.P., a Delaware limited partnership (“CRG Parallel Fund
A”), CRG Partners III (Cayman) Unlev AIV I L.P., a Cayman Islands exempted limited partnership (“CRG Unlev AIV”), CRG Partners III (Cayman) Lev AIV I L.P., a Cayman Islands exempted limited partnership (“CRG Lev AIV”), and
CRG Partners III Parallel Fund “B” (Cayman) L.P., a Cayman Islands exempted limited partnership (“CRG Parallel Fund B” and collectively with CRG Parallel Fund A, CRG Unlev AIV and CRG Lev AIV, the “CRG Funds”). Except
as otherwise specified in this Amendment No. 1, all items in the Schedule 13D remain unchanged. All capitalized terms used herein and not otherwise defined have the meanings ascribed to such terms in the Schedule 13D.
The Reporting Persons are filing this Amendment No. 1 to report certain changes in their beneficial ownership of the common stock, par value $0.001 per
share (the “Common Stock”), of T2 Biosystems, Inc., a Delaware corporation (the “Issuer”) as result of certain transactions in Common Stock of the Issuer.
Item 3. Source and Amount of Funds or Other Consideration
The response to Item 3 in the Schedule 13D is hereby amended and restated as follows:
The information set forth in Items 5 and 6 of this Schedule 13D is hereby incorporated by reference in its entirety into this Item 3.
All of the shares reported on this Schedule 13D were acquired from the Issuer in exchange for the Reporting Persons’ cancellation of outstanding loans to
the Issuer under that certain Term Loan Agreement, dated as of December 30, 2016, as amended, by and among the Issuer and CRG Servicing LLC, as administrative agent and collateral agent, and the lenders named therein. The most recent
acquisitions occurred on April 12, 2024 and May 3, 2024. Refer to the Issuer’s current reports on Form 8-K filed on July 6, 2023, February 15, 2024, April 18, 2024 and May 6,
2024 for additional information.
Item 5. Interest in Securities of the Issuer
The response to Item 5 in the Schedule 13D is hereby amended and restated as follows:
The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Schedule 13D and the information set forth or incorporated in Items
2 and 3 of this Schedule 13D is incorporated by reference in its entirety into this Item 5.
By virtue of the relationships among the Reporting Persons
described herein, the Reporting Persons may be deemed to constitute a group within the meaning of Section 13(d)(5) of the rules and regulations promulgated by the Securities and Exchange Commission pursuant to the Exchange Act. As such,
pursuant to Rule 13d-3 under the Exchange Act, such group may be deemed to beneficially own an aggregate of 8,853,173 shares of Common Stock, representing in the aggregate approximately 65.4% of the issued and
outstanding shares of Common Stock, as calculated pursuant to Rule 13d-3 under the Exchange Act.
Except as set
forth in this Schedule 13D, none of the Reporting Persons has effected any transactions in Common Stock during the last 60 days.
No other person is known
to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the shares of Common Stock beneficially owned by any of the Reporting Persons.